complement therapeutics

Novartis’ iptacopan hits the mark in rare kidney disease C3G

https://pharmaphorum.com/news/novartis-iptacopan-hits-the-mark-in-rare-kidney-disease-c3g/

Apellis reports mixed data with eye drug, but plans to file anyway

https://pharmaphorum.com/news/apellis-reports-mixed-data-with-eye-drug-but-plans-to-file-anyway/

AZ’s Alexion plans hit a snag as Ultomiris flunks ALS trial

https://pharmaphorum.com/news/azs-alexion-takeover-hits-a-snag-as-ultomiris-flunks-als-trial/

EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH

https://pharmaphorum.com/news/eha21-novartis-trumpets-iptacopan-as-oral-alternative-to-antibodies-in-pnh/

3rd Annual Complement-based Drug Development Summit 2019

https://pharmaphorum.com/events/3rd-annual-complement-based-drug-development-summit-2019/

Close in 10 seconds

Pharmaphorum.com

Search